Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL9 | O00512 | 2/20 | 0.36 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | PROKR1 | Q8TCW9 | 9/20 | 0.35 |
| ▸ | NAMPT | P43490 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3435942 | 0.87 | ALDH1A1 (0.35) | BCL9CTNNB1ALDH1A1LMNATDP1 | |
| SCHEMBL6522421 | 0.86 | CNR2 (0.37) | ALDH1A1 | |
| SCHEMBL3410172 | 0.84 | PROKR1 (0.38) | ALDH1A1LMNATDP1PROKR1NPC1 | |
| SCHEMBL6524057 | 0.73 | AR (0.34) | — | |
| SCHEMBL6519249 | 0.73 | PDE4B (0.42) | ALDH1A1LMNASCN9A | |
| SCHEMBL3435244 | 0.69 | PDE4B (0.39) | BCL9CTNNB1ALDH1A1PROKR1NAMPT | |
| SCHEMBL4099888 | 0.66 | RAB9A (0.57) | ALDH1A1LMNAPROKR1NPC1RAB9A | |
| SCHEMBL30522321 | 0.63 | PARP1 (0.54) | — | |
| SCHEMBL1422381 | 0.62 | PARP1 (0.49) | BCL9CTNNB1 | |
| SCHEMBL16423440 | 0.62 | SCD (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362030-B2 | Tricyclic derivatives as inhibitors of poly(ADP-ribose) polymerase (PARP) | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.R.L. (IT) | 2013-01-29 | — | — | US | disclosed |
| US-20110053911-A1 | TRICYCLIC DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.R.L. (IT) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053911-A1 | TRICYCLIC DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | PARP1, PARP2, PARP11 | BCL9 1909/4885CTNNB1 875/4885ALDH1A1 305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.